Clinical trial of trans-arterial administration of LAK and IL-2 to patient with hepatocellural carcinoma - Case reports.

達司, 小松; 克巳, 山内; 潔, 長谷川; 隆二, 古川; 敏己, 中西; 正, 次田; 晴臣, 武藤; 義憲, 磯部; 茂治, 田中; 広司, 長田; 勝, 清水; 裕, 小幡

doi:10.2957/kanzo.28.477

Acta hepatologica Japonica

1987

DOI: 10.2957/kanzo.28.477

|View full text |Cite

Clinical trial of trans-arterial administration of LAK and IL-2 to patient with hepatocellural carcinoma - Case reports.

小松達司¹,

山内克巳²,

長谷川潔³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1989

1992

Publication Types

Select...

Article3

Relationship

Self Cite1

Independent2

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have also found (Komatsu et al, 1987(Komatsu et al, , 1990) that LAK cell injections via catheter into the hepatic artery resulted in tumor regression in some hepatocellular carcinoma (HCC) patients. Similar results were reported by others (Okuno et al, 1986;Ishikawa et al, 1988;Onishi et al, 1989).…”

mentioning

confidence: 85%

“…Rosenberg first reported (Lotze et al, 1981) that systemic injection of interleukin-2-activated killer cells (LAK cells) has a potent therapeutic effect in cancer patients and further reports have since appeared (Rosenberg et al, 1985(Rosenberg et al, , 1986a(Rosenberg et al, , 1987. We have also found (Komatsu et al, 1987(Komatsu et al, , 1990) that LAK cell injections via catheter into the hepatic artery resulted in tumor regression in some hepatocellular carcinoma (HCC) patients. Similar results were reported by others (Okuno et al, 1986;Ishikawa et al, 1988;Onishi et al, 1989).…”

mentioning

confidence: 89%

See 1 more Smart Citation

Induction of autologous tumor‐specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization

Aruga¹,

Yamauchi

Takasaki³

et al. 1991

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

To generate autologous-tumor-specific cytotoxic T cells (CTL), peripheral blood mononuclear cells (PBMC) obtained from cancer patients were cultivated with autologous tumor cells for 5 days, and restimulated with interleukin-2 for another 5 days. Subsequently, their cytotoxic activity was examined by an in vitro cytotoxic test as well as by Winn's assay utilizing nude mouse transplanted autologous tumors. The present results demonstrated that these in vitro-stimulated cells were able to kill autologous tumor cells but not allogeneic tumors, and that they also inhibited the growth of transplanted autologous tumors in the nude mouse. Their cytotoxic activity was completely abrogated by pre-treatment with either anti-CD3 or anti-CD8, but not with anti-CD4, plus complement. Based on these studies, we injected these CTL via the hepatic artery into patients having either nonresected tumors or recurrent tumors in the liver. Among 15 treated patients (13 with hepatocellular carcinoma and 2 with metastatic liver cancer) 2 complete responses, 3 partial responses and 4 minor responses were observed. During the 6 to 25 months following injection of CTL, no definite signs of tumor recurrence or regrowth were demonstrated in these 5 responding patients (complete plus partial).

show abstract

mentioning

confidence: 85%

mentioning

confidence: 89%

Induction of autologous tumor‐specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization

Aruga¹,

Yamauchi

Takasaki³

et al. 1991

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Localization of tumor-infiltrating lymphocytes in patients with malignant liver tumors.

Takayama

Makuuchi

Sekine

1989

Jpn. J. Clin. Immunol.

View full text Add to dashboard Cite

[Summary]The two cases with malignant liver tumors were investigated to show the in vivo distribution of tumor-infiltrating lymphocytes (TIL) transferred via hepatic artery.Recombinant interleukin-2 and anti-CD3 antibody activated TIL, labeled with "'In, were injected into the hepatic artery through an Infuse-A-Port.In a patient with hepatocellular carcinoma, the radioactivities in the area corresponding to tumor site were significantly higher than those in the non-cancerous portion of the liver, at least, until 48 hours after injection.Similar result was observed in a patient with metastatic liver tumors from rectal cancer.This preliminary result indicates that an intra-arterial transfer will be preferable to acquire further accumulation of TIL at tumor sites in the liver.

show abstract

Two Cases of Hepatocellular Carcinoma Presented Rapid Progression of Lung Metastatic Lesions after Interruption of the Continuous Infusion Therapy of Recombinant Interleukin 2 with Single-shot Injection of Adriamycin and Lipiodol.

淳¹,

秀彦²,

正之³

et al. 1992

Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical trial of trans-arterial administration of LAK and IL-2 to patient with hepatocellural carcinoma - Case reports.

Cited by 3 publications

References 9 publications

Induction of autologous tumor‐specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization

Induction of autologous tumor‐specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization

Localization of tumor-infiltrating lymphocytes in patients with malignant liver tumors.

Two Cases of Hepatocellular Carcinoma Presented Rapid Progression of Lung Metastatic Lesions after Interruption of the Continuous Infusion Therapy of Recombinant Interleukin 2 with Single-shot Injection of Adriamycin and Lipiodol.

Contact Info

Product

Resources

About